CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-23 | Torti Frank President and Vant Chair | Grant or award | +175,380 | $22.45 | $3.9M | 13,911,927 |
| 2025-12-23 | Pulik Richard CFO | Option exercise | +260,000 | $3.85 | $1.0M | 646,144 |
| 2025-12-23 | Pulik Richard CFO | Sale | −260,000 | $22.45 | $5.8M | 386,144 |
| 2025-12-23 | Pulik Richard CFO | Sale | −146,731 | $22.39 | $3.3M | 239,413 |
| 2025-12-23 | Pulik Richard CFO | Option exercise · Stock Option (Right to Buy) | −260,000 | 740,000 | ||
| 2025-12-23 | Venker Eric President & Immunovant CEO | Option exercise | +313,841 | $3.85 | $1.2M | 1,811,749 |
| 2025-12-23 | Venker Eric President & Immunovant CEO | Sale | −200,000 | $22.45 | $4.5M | 1,611,749 |
| 2025-12-23 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) | −313,841 | 5,562,682 | ||
| 2025-12-20 | Pulik Richard CFO | Shares withheld for taxes | −2,129 | $22.41 | $48K | 386,144 |
| 2025-12-17 | Sukhatme Mayukh President & CIO | Option exercise | +59,513 | $12.68 | $755K | 18,896,060 |
| 2025-12-17 | Sukhatme Mayukh President & CIO | Sale | −26,831 | $23.09 | $620K | 18,869,229 |
| 2025-12-17 | Sukhatme Mayukh President & CIO | Other disposition | −32,682 | $23.09 | $755K | 18,836,547 |
| 2025-12-17 | Sukhatme Mayukh President & CIO | Option exercise · Common Shares | −59,513 | 1,304,198 | ||
| 2025-12-17 | Gold Daniel Allen Director | Sale | −432,718 | $23.05 | $10.0M | 16,697,727 |
| 2025-12-17 | Gold Daniel Allen Director | Sale | −155,076 | $23.02 | $3.6M | 16,542,651 |
| 2025-12-17 | Gold Daniel Allen Director | Sale | −189,538 | $23.17 | $4.4M | 16,353,113 |
| 2025-12-17 | MANCHESTER KEITH S Director | Sale | −432,718 | $23.05 | $10.0M | 16,697,727 |
| 2025-12-17 | MANCHESTER KEITH S Director | Sale | −155,076 | $23.02 | $3.6M | 16,542,651 |
| 2025-12-17 | MANCHESTER KEITH S Director | Sale | −189,538 | $23.17 | $4.4M | 16,353,113 |
| 2025-12-17 | QVT Financial LP Director by Deputization | Sale | −432,718 | $23.05 | $10.0M | 16,697,727 |
Page 13 of 29 · 570 trades